"

About Targeted Genetics
Targeted Genetics Corporation develops molecular medicines for the
prevention and treatment of acquired and inherited diseases.com.

perils witha

* Bioethics at the Cutting Edge
This panel will feature Lori Knowles, Bioethics, Law and Policy
Consultant , University of Alberta, Canada; John Robertson, Vinson and
Elkins Chair in Law, University of Texas School of Law; Henry Greely,
Professor, Law, Stanford Law School; Lori Andrews, Distinguished
Professor of Law, Director of the Institute for Science, Law and
Technology, Chicago -Kent College of Law; and Simon Best, Chairman,
Ardana PLC, in a discussion about whether current systems of governance
are adequate to regulate emergent technologies that push the bounds of
scientific limits. Only reporters and
editors working full-time for print or broadcast news organizations may
register onsite with valid media credentials.
patent #6,897,045, titled "Adeno -Associated Virus Vectors," was issued to the
University of Iowa Research Foundation and is exclusively licensed to Targeted
Genetics. The patent covers the use of two AAV vectors to deliver DNA
sequences that, once inside a cell, are used to produce or regulate a single
protein."
"My laboratory focuses on understanding basic mechanisms of recombinant
AAV infection, including how AAV vectors enter cells, how the viral genome
gains access to the nucleus and how these genomes are used to make protein,"
said John F.

crg genetically

bio.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across the
United States and 31 other nations.

New Patent Covers Targeted Genetics' Approach to Increase Carrying Capacity of AAV Vectors

We then
engineered vectors in a manner that causes this assembly to join two pieces of
RNA that together serve as a template for regulating a single protein.

perils humgen

D.org/events/2006/reg/.

We are excited to be actively working with Targeted Genetics to
apply this technology toward the development of novel therapies genetic
diseases and vaccines.

worldviews bioethical

, Professor, Psychiatry and Director ,
Programs in Ethics, USUHS; Gary Cohen, MPH student; Michael Werner,
President, The Werner Group; T., Professor, Department of Anatomy and Cell
Biology, University of Iowa Carver College of Medicine and Director for the UI
Center for Gene Therapy. These statements, involve current expectations ,
forecasts of future events and other statements that are not historical facts.

pollination genetics

To
register, please visit http://www.org/events/2006. Engelhardt, Ph. You
should not rely unduly on these forward -looking statements, which apply only
as of the date of this release.

geekiness genetics

, Director, Tuskegee University National Center for Bioethics
in Research and Health Care, will discuss the inclusion of minorities in
clinical trials and how to best ensure that minorities can avail
themselves of the benefits of the coming world of personalized medicine. All freelancers and online
publications must register in advance by Friday, March 31, 2006. BIO members are involved in the research
and development of healthcare, agricultural, industrial and environmental
biotechnology products.
While these approaches can be applied to some genes, the technology covered by
this patent significantly expands the potential application of AAV vectors by
providing a more flexible method to deliver genes and their associated
regulatory elements that are larger than the normal carrying capacity of these
vectors. Engelhardt further stated, "In the case of this patent, we first
recognized that RNA processing provided an interesting mechanism to join
together RNA sequences derived from two different AAV vectors. In
particular, the statements regarding the Company's pipeline and potential
application of this patent to any future product candidates are
forward-looking statements.

bioethical supposes

, Executive Vice President and
Chief Scientific Officer of Targeted Genetics.

worldviews genetics

D., J. We undertake no duty to publicly announce or
report revisions to these statements as new information becomes available that
may change our expectations.

assertions biowarfare

,
President, National Medical Association; and Vanessa Northington Gamble
M.
"We believe that the combined attributes of persistent expression and a
good safety profile make AAV vectors the vector of choice in the gene-transfer
treatment of a wide variety of chronic diseases and for the development of
viral vaccines," said Barrie J.

Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This release contains forward -looking statements regarding our
intellectual property, research programs and clinical trials, our product
development and our potential development platforms including AAV vectors and
other statements about our plans, objectives, intentions and expectations.

biosafety biowarfare

D.

* Management of Conflicts of Interest
Panelists Edmund Howe, M. SEATTLE, Targeted Genetics Corporation
(Nasdaq: TGEN ) today announced the issuance of another patent related to the
Company's leading adeno-associated virus (AAV) technology platform. "To date we have been able to
address the size constraint of AAV vectors for our product development
programs by utilizing small promoter elements or by modifying DNA sequences to
reduce their size without affecting the protein that ultimately is produced."
Dr.

genetically genetics

The April 10 Bioethics Track will include these dynamic panels:

* The Research Imperative: A Curse or a Cure?
Daniel Callahan, co-founder of The Hastings Center and author of "What
Price Better Health? Hazards of the Research Imperative;" Ronald Bailey,
science correspondent for Reason magazine, and author of "Liberation
Biology: The Scientific and Moral Case for the Bioetch Revolution;" Dan
Perry, Executive Director of the Alliance for Aging Research; and C. For more information about Targeted
Genetics, visit its website at http: //www.

consortia disadvantages

Recognizing that there is more to biotechnology than science and business,
BIO 2006 offers considerable programming about the social and ethical
implications of applications of biotechnology .

* Personalized Medicine, Race-Based Drug Development and the Dilemma of,
and Ethical Need for, Including Minorities in Clinical Trials
Panelists Osagie Imasogie, Senior Managing Partner, Phoenix IP Ventures;
Michael Loberg, President and CEO, NitroMed, Inc. Ph. The Company has
clinical product development programs targeting AIDS prophylaxis and
inflammatory arthritis .

elsi genetic

D. The Company also has a promising pipeline of
preclinical product development programs focused on hyperlipidemia, congestive
heart failure, and Huntington's disease.
Inaccurate assumptions and known and unknown risks and uncertainties can
affect the accuracy of forward-looking statements .

biosafety genetic

Carter, Ph.

genetics witha

D. We
recognized that this approach is very powerful because it allows us to double
the size of the genes and their regulatory sequences that one can deliver with
AAV vectors.targetedgenetics .

credible assertions

D., MPH, MTS, FACS, FCCM,
Managing Partner, Cordova Ventures; and moderator, Elizabeth Price,
Attorney, Alston + Bird LLP, will address the characteristics of
conflicts that make them disabling or non-disabling and how and when
such conflicts can be cured.S. "Much of what we learn through elucidating these
pathways may help to enhance the use of AAV vectors as delivery systems for
treating a variety of diseases.

pollination geekiness

Boyd Clarke, a biotech executive , will speak frankly about whether there
should be any limits to the resources, goals or methods of medical
research.

Advance media registration for BIO 2006 is now available online . U. This approach allows AAV vectors to be used to deliver genes and
their regulatory sequences that ordinarily would be too large to fit inside a
single vector, expanding the potential applications of AAV-based gene
delivery.

nfsd witha

geekiness genetically

patenting eugenics

Prominent Bioethicists and Academics Highlight BIO 2006 Bioethics Track

WASHINGTON, A group of leading bioethics
professionals, academics and thought leaders will be assembled to participate
in a variety of panel discussions on bioethics issues that confront the
industry at BIO 2006.D.

genetically perils

Additional
program information may be found online at http://www. Factors that could affect
our actual results include, but are not limited to, results of animal research
are not necessarily indicative of results in humans, the timing, nature and
results of our research , potential development of alternative technologies or
more effective products by competitors, our ability to obtain and maintain
regulatory or institutional approvals, our ability to obtain, maintain and
protect our intellectual property and our ability to raise capital when
needed, as well as other risk factors described in the section entitled
"Factors Affecting Our Operating Results, Our Business and Our Stock Price" in
our Quarterly Report on Form 10-Q for the period ended March 31 , 2005.

assertions disadvantages

Registration is complimentary for credentialed members of the news media.

tsukuba assertions

D. Forcht Dagi, M .

biowarfare consortia

BIO 2006, the BIO annual international convention, will
take place April 9-12 at Chicago's McCormick Place.; Sandra Gadson, M.bio.